Xbrane And Stada’s Ranibizumab Snapped Up In North America

Bausch + Lomb Licenses Biosimilar Lucentis Rival For US And Canada

 
• By Dave Wallace

Bausch + Lomb has struck a deal for US and Canadian rights to the Xlucane ranibizumab biosimilar rival to Lucentis that is being developed by Xbrane Biopharma and Stada.

Eye
Eye care specialist Bausch + Lomb has struck a deal for Xbrane and Stada’s Ranibizumab • Source: Shutterstock

More from Biosimilars

More from Products